Navigation Links
ClinStar, LLC Establishes New Office on the US East Coast
Date:7/19/2011

SAN FRANCISCO, July 19, 2011 /PRNewswire/ -- ClinStar, LLC, an established CRO providing clinical research services in the emerging markets of Russia and Eastern Europe to the pharmaceutical and biotechnology industry, announced today the opening of a new regional office on the East Coast of the United States.

(Photo:  http://photos.prnewswire.com/prnh/20110719/SF36975LOGO)

As a second US location to its headquarters in San Francisco, CA, ClinStar's new office is located at 1000 Park Forty Plaza, Durham, NC. In addition to offering adequate space to centralize ClinStar's regional workforce, the new facility was chosen in large part because of its flexibility to accommodate the company's future growth.

According to President and CEO David Passov, "This is the realization of a major long-term business goal for ClinStar. Our new office further solidifies our commitment to offer our clients the local expertise and knowledge they need to successfully conduct clinical trials in Russia and Eastern Europe while ensuring our business operates in accordance with the proven business and management principles practiced in the West."  

"We are thrilled with the opening of our new office," says Erin King, Executive Director Business Development and Marketing. This move is just one of several important initiatives positioning ClinStar as the leading provider of clinical research services in Russia, Ukraine and parts of Eastern Europe. Our new facility affords not only centralized office space for our employees, but also upscale conference space for hosting meetings with our customers."  

About ClinStar, LLC

ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics, with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus with total staff of over 300 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at www.clinstar.com.


'/>"/>
SOURCE ClinStar, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
2. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
3. Pharmaxis Establishes Named Patient Program for Bronchitol
4. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
5. BD Establishes $1.2 Million Fund for Haiti Earthquake Relief Efforts
6. FUJIFILM Establishes Medical Informatics Organization
7. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
8. Mach 7 Technologies Establishes New Headquarters in Burlington, VT
9. Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
10. HUYA Biosciences Establishes Strategic Partnership with Sun Yat-sen Universitys School of Pharmaceutical Sciences
11. Varian Medical Systems Establishes Radiotherapy Training Center in Mumbai, India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... LEXINGTON, Mass. , March 27, 2017   Pulmatrix, ... innovative inhaled therapies to address serious pulmonary diseases, today announced ... allergic fungal disease, cystic fibrosis and asthma to its ... Richard B. Moss , MD, ... former Director of the Cystic Fibrosis Center at Stanford University, ...
(Date:3/27/2017)... March 27, 2017 The global ... USD 16.0 billion by 2025, according to a new ... of chronic diseases is anticipated to be responsible for ... thereby widens the scope for growth during the forecast ... population, which is highly susceptible to chronic diseases, is ...
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of ... were things that his parents and teachers had asked of him that he had neglected ... going to defy the Almighty Creator. There were some who would have felt themselves to ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Bruce Trimble and Michelle Parker ... a referral. Trimble Dental offers a variety of services to meet each patient’s ... patients have discolored, crooked or missing teeth in Eau Claire, WI, Drs. Trimble ...
(Date:3/27/2017)... White Plains, NY (PRWEB) , ... March 27, 2017 , ... ... honoring Root Canal Awareness Week by teaching their patients about the key role this ... canal therapy from an experienced endodontist. To better serve those who need a ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
Breaking Medicine News(10 mins):